Pune, India -- (SBWIRE) -- 05/09/2018 -- Global radiotherapy market is expected to reach USD 9.3 billion by 2024 from USD 5.2 billion in 2016, at a CAGR of 7.5% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Beam radiotherapy market has the largest market segment in radiotherapy market.

To request a free sample copy or view summary of this report, click the link below @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiotherapy-market

The global radiotherapy market is highly concentrated to a big player and rest to local players who cater to domestic markets only. Varian Medical Systems, Inc. dominated the radiotherapy market accounting for a highest market share in 2016. Other players in this market include Elekta AB, Accuray, Inc., CIVCO Medical Solutions, Brainlab AG, C. R. Bard, Inc., IsoRay Medical, Inc., Nordion, Inc., RaySearch Laboratories AB, PRECISIS AG, Mevion Medical Systems, Inc., Technicas Radiofiscas S.L., Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Mitsubishi Electric Corporation, ProNova Solutions, LLC, ProTom International.

To Know More About Report Visit @ https://youtu.be/LK0mFjSWvGE

Varian Medical Systems, Inc.:

Founded in 1948 as Varian Medical Systems, Inc. and head quartered in California, U.S. is a provider of radiotherapy, proton therapy and brachytherapy. Varian also supplies X-ray imaging components for medical, scientific, cargo screening and industrial applications. Varian operates through two business segments: oncology systems and imaging components.

Recent developments:

1. In October 2016, Varian Medical Systems, Inc. and McKesson Specialty Health announced a strategic agreement for the distribution and servicing of Varian advanced radiotherapy equipment and software over a three period across "The US Oncology Network" and "Vantage Oncology" affiliated sites of care.

2. In October 2016, Varian Medical Systems, Inc. announced the launch of first of its kind 360 Oncology care management platform, the first software system designed to integrate and coordinate key elements of cancer so patients and their cancer teams can collaborate on achieving the best outcomes.

Elekta AB:

Founded in 1972 and headquartered in Stockholm, Sweden by Lars Leksell and Laurent Leksell. Elekta is a provider of human care, which specialises in the treatment of cancers and brain disorders. It provides oncologists, radiation therapists, neurosurgeons, and other medical specialists with the aid of clinical solutions and tools.

Have Any Query? Inquire here @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiotherapy-market

Recent Developments:

1. In December 2016, Elekta, Stockholm's County Council and New Karolinska Solna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research and education and training within advanced radiation therapy.

2. In March 2016, Elekta announced the strategic partnership with Genesis care where, the later will acquire Elekta's Leksell Gamma Knife Icon radiosurgery systems, Versa HD linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by Genesis Care cancer treatment centres in Australia, the UK and new markets.

Accuray:

Accuray, Inc. is the premier radiation oncology company which develops, manufactures and sells personalized treatment solutions such as the cyberKnife and tomotherapy systems, which are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy. The cyberKnife system is designed to combine continual image guidance technology with a compact linear accelerator, or linac, which has the ability to move in three dimensions according to the treatment plan. The tomotherapy system operates on a ring gantry and combines integrated computed tomography, or CT, imaging with intensity modulated radiation therapy, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. Accuray was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Recent Developments:

1. In August 2016, Accuray announced the CE approval of Radixact Treatment Delivery System, Accuray Precision Treatment Planning System and iDMS Data Management System in Europe.
2. In June 2016, Accuray Incorporated announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact Treatment Delivery Platform. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.

Questions? We'll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-radiotherapy-market

TABLE OF CONTENTS GLOBAL RADIOTHERAPY MARKET

1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL RADIOTHERAPY MARKET
1.1.1. CURRENCY AND PRICING
1.1.2. LIMITATION
1.1.3. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. GROWING PREVALENCE OF CANCER
3.1.2. RISING AGEING POPULATION
3.1.3. UNHEALTHY LIFESTYLE
3.1.4. MERGERS AND ACQUISITIONS TO EXPAND BUSINESS

3.2. RESTRAINTS

3.2.1. REGULATORY SCENARIO
3.2.2. HIGH COST OF RADIOTHERAPY

3.3. OPPORTUNITIES

3.3.1. GROWING MEDICAL TOURISM IN ASIA
3.3.2. EMERGING MARKET

3.4. CHALLENGES

3.4.1. SIDE-EFFECTS OF RADIOTHERAPY
3.4.2. REQUIREMENT OF TRAINED STAFF

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL RADIOTHERAPY MARKET, BY THERAPY TYPE

6.1. OVERVIEW
6.2. BEAM RADIOTHERAPY, BY THERAPY TYPE
6.3. BRACHYTHERAPY, BY THERAPY TYPE

7. GLOBAL RADIOTHERAPY MARKET, BY PRODUCT TYPE

7.1. OVERVIEW
7.2. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT TYPE
7.3. GLOBAL INTERNAL BEAM RADIOTHERAPY MARKET, BY PRODUCT TYPE
7.4. GLOBAL RADIOTHERAPY SOFTWARES MARKET, BY PRODUCT TYPE

8. GLOBAL RADIOTHERAPY MARKET, BY INDICATION

8.1. OVERVIEW

9. GLOBAL RADIOTHERAPY MARKET, BY GEOGRAPHY

9.1. OVERVIEW

9.2. NORTH AMERICA RADIOTHERAPY MARKET SNAPSHOT: 2016

9.2.1. U.S. RADIOTHERAPY MARKET
9.2.2. CANADA RADIOTHERAPY MARKET
9.2.3. MEXICO RADIOTHERAPY MARKET

9.3. EUROPE RADIOTHERAPY MARKET

9.3.1. GERMANY RADIOTHERAPY MARKET
9.3.2. FRANCE RADIOTHERAPY MARKET
9.3.3. U.K. RADIOTHERAPY MARKET
9.3.4. SWITZERLAND RADIOTHERAPY MARKET
9.3.5. ITALY RADIOTHERAPY MARKET
9.3.6. RUSSIA RADIOTHERAPY MARKET
9.3.7. NETHERLANDS RADIOTHERAPY MARKET
9.3.8. SPAIN RADIOTHERAPY MARKET
9.3.9. BELGIUM RADIOTHERAPY MARKET
9.3.10. TURKEY RADIOTHERAPY MARKET

9.4. APAC RADIOTHERAPY MARKET SNAPSHOT: 2016

9.4.1. JAPAN RADIOTHERAPY MARKET
9.4.2. CHINA RADIOTHERAPY MARKET
9.4.3. INDIA RADIOTHERAPY MARKET
9.4.4. SOUTH KOREA RADIOTHERAPY MARKET
9.4.5. AUSTRALIA RADIOTHERAPY MARKET
9.4.6. THAILAND RADIOTHERAPY MARKET
9.4.7. MALAYSIA RADIOTHERAPY MARKET
9.4.8. INDONESIA RADIOTHERAPY MARKET
9.4.9. SINGAPORERADIOTHERAPY MARKET
9.4.10. PHILIPPINES RADIOTHERAPY MARKET

9.5. SOUTH AMERICA RADIOTHERAPY MARKET SNAPSHOT: 2016

9.5.1. BRAZIL RADIOTHERAPY MARKET

9.6. MEA RADIOTHERAPY MARKET SNAPSHOT: 2016

9.6.1. SAUDI ARABIA RADIOTHERAPY MARKET

10. GLOBAL RADIOTHERAPY MARKET, COMPANY SHARE

10.1. COMPANY SHARE ANALYSIS: GLOBAL
10.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
10.3. COMPANY SHARE ANALYSIS: EUROPE
10.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

11. COMPANY PROFILES

11.1. VARIAN MEDICAL SYSTEMS, INC.

11.1.1. COMPANY OVERVIEW

11.1.2. SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

11.1.3. DRIVERS EXPLAINED

11.1.3.1. DIVERSE PRODUCT PORTFOLIO:
11.1.3.2. STRONG RESEARCH AND DEVELOPMENT CAPABILITIES:

11.1.4. WEAKNESSES EXPLAINED

11.1.4.1. DEPENDENCE ON LIMITED NUMBER OF SUPPLIERS:

11.1.5. OPPURTUNITIES EXPLAINED

11.1.5.1. VARIAN COULD EXPAND ITS POSITION WITH IMAGING COMPONENTS BUSINESS' SPIN-OFF:
11.1.5.2. ACQUISITIONS LIKELY TO ENHANCE VARIAN'S ONCOLOGY AND IMAGING BUSINESSES:
11.1.5.3. EXPANSION IN OPERATIONS IN THE U.S.:
11.1.5.4. INCREASING INCIDENCE OF CANCER TO DRIVE GLOBAL RADIATION THERAPY EQUIPMENT MARKET:

11.1.6. THREATS EXPLAINED

11.1.6.1. INTENSE COMPETITION COULD AFFECT VARIAN'S MARKET SHARE AND RESULTS OF OPERATION:
11.1.6.2. INCREASING MEDICAL COSTS IN CANCER TREATMENT AND CARE: 259

11.1.7. REVENUE ANALYSIS

11.1.8. PRODUCT PORTFOLIO

11.1.9. RECENT DEVELOPMENTS

11.1.10. DATA BRIDGE ANALYSIS

11.2. ELEKTA AB

11.2.1. COMPANY OVERVIEW
11.2.2. REVENUE ANALYSIS
11.2.3. PRODUCT PORTFOLIO
11.2.4. RECENT DEVELOPMENTS
11.2.5. DATA BRIDGE ANALYSIS

11.3. NANOBIOTIX

11.3.1. COMPANY OVERVIEW
11.3.2. REVENUE ANALYSIS
11.3.3. PRODUCT PORTFOLIO
11.3.4. RECENT DEVELOPMENTS
11.3.5. DATA BRIDGE ANALYSIS

11.4. ACCURAY, INC.

11.4.1. COMPANY OVERVIEW
11.4.2. REVENUE ANALYSIS
11.4.3. PRODUCT PORTFOLIO
11.4.4. RECENT DEVELOPMENTS

11.5. BRAINLAB AG

11.5.1. COMPANY OVERVIEW

11.5.2. SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

11.5.3. DRIVERS EXPLAINED

11.5.3.1. STRONG PARTNER NETWORK:
11.5.3.2. ESTABLISHED PRESENCE IN MARKETS:

11.5.4. WEAKNESSES EXPLAINED

11.5.4.1. PRODUCT SAFETY CONCERNS:

11.5.5. OPPURTUNITIES EXPLAINED

11.5.5.1. STRATEGIC INITIATIVES:

11.5.6. THREATS EXPLAINED

11.5.6.1. RAPID TECHNOLOGICAL CHANGES:
11.5.6.2. STRINGENT GOVERNMENT REGULATIONS:

11.5.7. REVENUE ANALYSIS

11.5.8. PRODUCT PORTFOLIO

11.5.9. RECENT DEVELOPMENTS

11.6. ION BEAM APPLICATIONS SA

11.6.1. COMPANY OVERVIEW
11.6.2. REVENUE ANALYSIS
11.6.3. PRODUCT PORTFOLIO
11.6.4. RECENT DEVELOPMENTS

11.7. MEVION MEDICAL SYSTEMS, INC.

11.7.1. COMPANY OVERVIEW
11.7.2. REVENUE ANALYSIS
11.7.3. PRODUCT PORTFOLIO
11.7.4. RECENT DEVELOPMENTS

11.8. ISORAY MEDICAL, INC.

11.8.1. COMPANY OVERVIEW
11.8.2. REVENUE ANALYSIS
11.8.3. PRODUCT PORTFOLIO
11.8.4. RECENT DEVELOPMENTS

11.9. NORDION (CANADA) INC.

11.9.1. COMPANY OVERVIEW

11.9.2. SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

11.9.3. DRIVERS EXPLAINED

11.9.3.1. ESTABLISHED PRESENCE IN GAMMA IRRADIATION INDUSTRY:

11.9.4. WEAKNESSES EXPLAINED

11.9.4.1. RADIATION EXPOSURE CLAIMS AND OTHER DISPUTES:

11.9.5. OPPURTUNITIES EXPLAINED

11.9.5.1. STRATEGIC INITIATIVES:

11.9.6. THREATS EXPLAINED

11.9.6.1. RAPID TECHNOLOGICAL CHANGES:
11.9.6.2. STRINGENT GOVERNMENT REGULATIONS:
11.9.6.3. STIFF COMPETITION:

11.9.7. REVENUE ANALYSIS

11.9.8. PRODUCT PORTFOLIO

11.9.9. RECENT DEVELOPMENTS

11.10. RAYSEARCH LABORATORIES AB

11.10.1. COMPANY OVERVIEW
11.10.2. REVENUE ANALYSIS
11.10.3. PRODUCT PORTFOLIO
11.10.4. RECENT DEVELOPMENTS

11.11. PRECISIS AG

11.11.1. COMPANY OVERVIEW
11.11.2. REVENUE ANALYSIS
11.11.3. PRODUCT PORTFOLIO
11.11.4. RECENT DEVELOPMENTS

12. RELATED REPORTS

Read more about the Global Radiotherapy Market Landscape: http://databridgemarketresearch.com/reports/global-radiotherapy-market/

Related Report

Europe Radiotherapy Market – Industry Trends and Forecast to 2024

Europe Radiotherapy Market, By Therapy (Beam Radiotherapy (IGRT, IMRT, VMAT, Tomotherapy, 3D CRT, Proton Beam, Stereotactic), Brachytherapy (LDR, HDR), Systemic Radiotherapy), By Product Type (Cyberknife, Gammaknife, Linac, Proton Beam, Systemic Radiotherapy, Seeds, Afterloaders), By Indication (Prostate & Breast Cancer)), By Country (Germany, France, U.K., Spain, Italy, Russia, Netherlands, Turkey, Belgium, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/europe-radiotherapy-market/

About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com